Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Flat sales at Guerbet in first nine months:

This article was originally published in Clinica

Executive Summary

Sales at French contrast agent manufacturer Guerbet were flat at Fr 792 million ($158 million) in the first nine months of 1996. Net profits, however, were down 17% from Fr 40 million in 1995 to Fr 33 million this year. President Michel Guerbet blames cost control measures in France and a general reduction in prices. Xenetix, the company's non-ionic X-ray agent, recorded the strongest growth over the period, with sales up 400% compared with 1995. Xenetix now represents 11% of Guerbet's turnover. International sales increased 6% in the first nine months.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT089368

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel